<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s0{background-color:#ffffff;text-align:left;font-weight:bold;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s4{border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'docs-Roboto',Arial;font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s3{border-left: none;border-right: none;background-color:#ffffff;}.ritz .waffle .s1{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s2{border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}</style><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header freezebar-origin-ltr"></th><th id="789029412C0" style="width:100px;" class="column-headers-background">A</th><th id="789029412C1" style="width:100px;" class="column-headers-background">B</th><th id="789029412C2" style="width:100px;" class="column-headers-background">C</th></tr></thead><tbody><tr style="height: 20px"><th id="789029412R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">1</div></th><td class="s0" dir="ltr">SGA</td><td class="s1" dir="ltr">Source</td><td class="s1" dir="ltr">GTG 31</td></tr><tr style="height: 20px"><th id="789029412R1" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">2</div></th><td></td><td></td><td></td></tr><tr style="height: 20px"><th id="789029412R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">3</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:898px;left:-1px">RISK FACTORS: All women should be assessed at booking for risk factors for a SGA fetus/neonate to identify those who require increased surveillance. </div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">4</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1498px;left:-1px">MAJOR risk factors: Women who have a major risk factor (Odds Ratio [OR] &gt; 2.0) should be referred for serial ultrasound measurement of fetal size and assessment of wellbeing with umbilical artery Doppler from 26–28 weeks of pregnancy . </div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">5</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:898px;left:-1px">MINOR Risk Factors: Women who have three or more minor risk factors should be referred for uterine artery Doppler at 20–24 weeks of gestation.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">6</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:698px;left:-1px">2ND TRIMESTER: 2nd trimester DS markers have limited predictive accuracy for delivery of a SGA neonate. </div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">7</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:898px;left:-1px">PAPP-A: A low level (&lt; 0.415 MoM) of the first trimester marker PAPP–A should be considered a major risk factor for delivery of a SGA neonate.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R7" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">8</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:7093px;left:-1px">UTERINE ARTERY: In high risk populations uterine artery Doppler at 20–24 weeks of pregnancy has a moderate predictive value for a severely SGA neonate. In women with an abnormal uterine artery Doppler at 20–24 weeks of pregnancy, subsequent normalisation of flow velocity indices is still associated with an increased risk of a SGA neonate. Repeating uterine artery Doppler is therefore of limited value. Women with an abnormal uterine artery Doppler at 20–24 weeks (defined as a pulsatility index [PI] &gt; 95th centile) and/or notching should be referred for serial ultrasound measurement of fetal size and assessment of wellbeing with umbilical artery Doppler commencing at 26–28 weeks of pregnancy. Women with a normal uterine artery Doppler do not require serial measurement of fetal size and serial assessment of wellbeing with umbilical artery Doppler unless they develop specific pregnancy complications, for example antepartum haemorrhage or hypertension. However, they should be offered a scan for fetal size and umbilical artery Doppler during the third trimester.  Uterine artery Doppler has limited accuracy to predict adverse outcome in SGA fetuses diagnosed during the third trimester.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R8" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">9</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1098px;left:-1px">UMBILICAL ARTERY: Serial ultrasound measurement of fetal size and assessment of wellbeing with umbilical artery Doppler should be offered in cases of fetal echogenic bowel. </div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R9" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">10</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:5025px;left:-1px">ABDOMINAL PALPATION: Abdominal palpation has limited accuracy for the prediction of a SGA neonate and thus should not be routinely performed in this context. Serial measurement of symphysis fundal height (SFH) is recommended at each antenatal appointment from 24 weeks of pregnancy as this improves prediction of a SGA neonate. SFH should be plotted on a customised chart rather than a population–based chart as this may improve prediction of a SGA neonate. Women with a single SFH which plots below the 10th centile or serial measurements which demonstrate slow or static growth by crossing centiles should be referred for ultrasound measurement of fetal size. Women in whom measurement of SFH is inaccurate (for example: BMI &gt; 35, large fibroids, hydramnios) should be referred for serial assessment of fetal size using ultrasound.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R10" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">11</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:4102px;left:-1px">SFH: Serial measurement of symphysis fundal height (SFH) is recommended at each antenatal appointment from 24 weeks of pregnancy as this improves prediction of a SGA neonate. SFH should be plotted on a customised chart rather than a population–based chart as this may improve prediction of a SGA neonate. Women with a single SFH which plots below the 10th centile or serial measurements which demonstrate slow or static growth by crossing centiles should be referred for ultrasound measurement of fetal size. Women in whom measurement of SFH is inaccurate (for example: BMI &gt; 35, large fibroids, hydramnios) should be referred for serial assessment of fetal size using ultrasound.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R11" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">12</div></th><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:798px;left:-1px">DIAGNOSIS: Fetal abdominal circumference (AC) or estimated fetal weight (EFW) &lt; 10th centile can be used to diagnose a SGA fetus.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R12" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">13</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1798px;left:-1px">CUSTOMISED CHARTS: Use of a customised fetal weight reference may improve prediction of a SGA neonate and adverse perinatal outcome. In women having serial assessment of fetal size, use of a customised fetal weight reference may improve the prediction of normal perinatal outcome.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R13" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">14</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1398px;left:-1px">ROUTINE 3rd TRIMESTER BIOMETRY: Routine measurement of fetal AC or EFW in the third trimester does not reduce the incidence of a SGA neonate nor does it improve perinatal outcome. Routine fetal biometry is thus not justified.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R14" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">15</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:998px;left:-1px">WASTING: Change in AC or EFW may improve the prediction of wasting at birth (neonatal morphometric indicators) and adverse perinatal outcome suggestive of FGR.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R15" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">16</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1998px;left:-1px">3 WEEKS APART: When using two measurements of AC or EFW to estimate growth velocity, they should be at least 3 weeks apart to minimise false–positive rates for diagnosing FGR. More frequent measurements of fetal size may be appropriate where birth weight prediction is relevant outside of the context of diagnosing SGA/FGR.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R16" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">17</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1198px;left:-1px">SERIAL SURVEILLANCE: Where the fetal AC or EFW is &lt; 10th centile or there is evidence of reduced growth velocity, women should be offered serial assessment of fetal size and umbilical artery Doppler.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R17" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">18</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1098px;left:-1px">EARLY SEVERE SGA: Offer referral for a detailed fetal anatomical survey and uterine artery Doppler by a fetal medicine specialist if severe SGA is identified at the 18–20 week scan.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R18" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">19</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1198px;left:-1px">KARYOTYPING: Karyotyping should be offered in severely SGA fetuses with structural anomalies and in those detected before 23 weeks of gestation, especially if uterine artery Doppler is normal.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R19" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">20</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1398px;left:-1px">INFECTIONS: Serological screening for congenital cytomegalovirus (CMV) and toxoplasmosis infection should be offered in severely SGA fetuses. Testing for syphilis and malaria should be considered in high risk populations.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R20" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">21</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:5194px;left:-1px">PREVENTION: Antiplatelet agents may be effective in preventing SGA birth in women at high risk of pre-eclampsia although the effect size is small. In women at high risk of pre-eclampsia, antiplatelet agents should be commenced at, or before, 16 weeks of pregnancy. There is no consistent evidence that dietary modification, progesterone or calcium prevent birth of a SGA infant. These interventions should not be used for this indication. Interventions to promote smoking cessation may prevent delivery of a SGA infant. The health benefits of smoking cessation indicate that these interventions should be offered to all women who are pregnant and smoke. Antithrombotic therapy appears to be a promising therapy for preventing delivery of a SGA infant in high-risk women. However there is insufficient evidence, especially concerning serious adverse effects, to recommend its use.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R21" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">22</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1098px;left:-1px">STEROIDS: Women with a SGA fetus between 24+0 and 35+6 weeks of gestation, where delivery is being considered, should receive a single course of antenatal corticosteroids.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R22" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">23</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:7129px;left:-1px">SGA SURVEILLANCE TIMING / FREQUENCY: In a high–risk population, the use of umbilical artery Doppler has been shown to reduce perinatal morbidity and mortality. Umbilical artery Doppler should be the primary surveillance tool in the SGA fetus. When umbilical artery Doppler flow indices are normal it is reasonable to repeat surveillance every 14 days. More frequent Doppler surveillance may be appropriate in a severely SGA fetus. When umbilical artery Doppler flow indices are abnormal (pulsatility or resistance index &gt; +2 SDs above mean for gestational age) and delivery is not indicated repeat surveillance twice weekly in fetuses with end–diastolic velocities present and daily in fetuses with absent/reversed end–diastolic frequencies. CTG should not be used as the only form of surveillance in SGA fetuses. Interpretation of the CTG should be based on short term fetal heart rate variation from computerised analysis. Ultrasound assessment of amniotic fluid volume should not be used as the only form of surveillance in SGA fetuses. Interpretation of amniotic fluid volume should be based on single deepest vertical pocket. Biophysical profile should not be used for fetal surveillance in preterm SGA fetuses.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R23" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">24</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:3685px;left:-1px">MCA and DV: In the preterm SGA fetus, middle cerebral artery (MCA) Doppler has limited accuracy to predict acidaemia and adverse outcome and should not be used to time delivery. In the term SGA fetus with normal umbilical artery Doppler, an abnormal middle cerebral artery Doppler (PI &lt; 5th centile) has moderate predictive value for acidosis at birth and should be used to time delivery. Ductus venosus Doppler has moderate predictive value for acidaemia and adverse outcome. Ductus venosus Doppler should be used for surveillance in the preterm SGA fetus with abnormal umbilical artery Doppler and used to time delivery</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R24" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">25</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:5525px;left:-1px">TIMING OF DELIVERY: In the preterm SGA fetus with umbilical artery AREDV detected prior to 32 weeks of gestation, delivery is recommended when DV Doppler becomes abnormal or UV pulsations appear, provided the fetus is considered viable and after completion of steroids. Even when venous Doppler is normal, delivery is recommended by 32 weeks of gestation and should be considered between 30–32 weeks of gestation. If MCA Doppler is abnormal, delivery should be recommended no later than 37 weeks of gestation. In the SGA fetus detected after 32 weeks of gestation with an abnormal umbilical artery Doppler, delivery no later than 37 weeks of gestation is recommended. In the SGA fetus detected after 32 weeks of gestation with normal umbilical artery Doppler, a senior obstetrician should be involved in determining the timing and mode of birth of these pregnancies. Delivery should be offered at 37 weeks of gestation.</div></td><td class="s3"></td><td class="s3"></td></tr><tr style="height: 20px"><th id="789029412R25" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">26</div></th><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:3354px;left:-1px">MODE OF DELIVERY: In the SGA fetus with umbilical artery AREDV delivery by caesarean section is recommended. In the SGA fetus with normal umbilical artery Doppler or with abnormal umbilical artery PI but end–diastolic velocities present, induction of labour can be offered but rates of emergency caesarean section are increased and continuous fetal heart rate monitoring is recommended from the onset of uterine contractions. Early admission is recommended in women in spontaneous labour with a SGA fetus in order to instigate continuous fetal heart rate monitoring.</div></td><td class="s3"></td><td class="s3"></td></tr></tbody></table></div>